A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...
About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback